Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes

Molecular Oncology

Volumn 6, Issue 5, 2012, Pages 494-506

  Holm, Karolina ^a   Grabau, Dorthe ^b   Lövgren, Kristina ^a   Aradottir, Steina ^a   Gruvberger Saal, Sofia ^a   Howlin, Jillian ^a   Saal, Lao H ^a   Ethier, Stephen P ^c   Bendahl, Pär Ola ^a   Stål, Olle ^d   Malmström, Per ^a   Fernö, Mårten ^a   Rydén, Lisa ^a   Hegardt, Cecilia ^a   Borg, Åke ^a   Ringnér, Markus ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

ANOVA; Breast cancer; DDFS; Epigenetics; ER; ES; EZH2; GEX; H3K27me3; IHC; Molecular subtypes; Polycomb; PR; PRC2; TMA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HISTONE H3; KI 67 ANTIGEN; MESSENGER RNA; TRANSCRIPTION FACTOR EZH2;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; WESTERN BLOTTING;

EID: 84866050864     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.06.002     Document Type: Article

References (70)

1. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., Salvesen H.B., Otte A.P., Akslen L.A. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 2006, 24:268-273.
2. Bediaga N.G., Acha-Sagredo A., Guerra I., Viguri A., Albaina C., Ruiz Diaz I., Rezola R., Alberdi M.J., Dopazo J., Montaner D., de Renobales M., Fernandez A.F., Field J.K., Fraga M.F., Liloglou T., de Pancorbo M.M. DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res. 2010, 12:R77.
3. Bodor C., O'Riain C., Wrench D., Matthews J., Iyengar S., Tayyib H., Calaminici M., Clear A., Iqbal S., Quentmeier H., Drexler H.G., Montoto S., Lister A.T., Gribben J.G., Matolcsy A., Fitzgibbon J. EZH2 Y641 mutations in follicular lymphoma. Leukemia 2011, 25:726-729.
4. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., Helin K. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006, 20:1123-1136.
5. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22:5323-5335.
6. Cai M.Y., Hou J.H., Rao H.L., Luo R.Z., Li M., Pei X.Q., Lin M.C., Guan X.Y., Kung H.F., Zeng Y.X., Xie D. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients. Mol. Med. 2011, 17:12-20.
7. Chang C.J., Yang J.Y., Xia W., Chen C.T., Xie X., Chao C.H., Woodward W.A., Hsu J.M., Hortobagyi G.N., Hung M.C. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011, 19:86-100.
8. Charafe-Jauffret E., Ginestier C., Monville F., Finetti P., Adelaide J., Cervera N., Fekairi S., Xerri L., Jacquemier J., Birnbaum D., Bertucci F. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006, 25:2273-2284.
9. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., Perou C.M., Ellis M.J., Nielsen T.O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst. 2009, 101:736-750.
10. Collett K., Eide G.E., Arnes J., Stefansson I.M., Eide J., Braaten A., Aas T., Otte A.P., Akslen L.A. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 2006, 12:1168-1174.
11. Derfoul A., Juan A., Difilippantonio M.J., Palanisamy N., Ried T., Sartorelli V. Decreased MicroRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion, and accumulation of the polycomb Ezh2 methyltransferase. Carcinogenesis 2011, 32:1607-1614.
12. Fernö M., Baldetorp B., Bendahl P.O., Borg å., Ewers S.B., Olsson H., Rydén S., Sigurdsson H., Killander D. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen-especially for progesterone receptor positive tumors with a high proliferation. Breast Cancer Res. Treat. 1995, 36:23-34.
13. Fernö M., Bendahl P.O., Brisfors A., Byman K., Ekeberg M., Ferraud L., Grankvist K., Hjalmers B., Nilsson A., Sellberg G., Skoog L., Stål O., Wingmo I. Intra- and inter-laboratory reproducibility of estrogen and progesterone receptor enzyme immunoassay in breast cancer cytosol samples-a Swedish multicenter study. Swedish Soc. Cancer Study Group Acta Oncol. 1997, 36:793-798.
14. Fernö M., Stål O., Baldetorp B., Hatschek T., Källström A.C., Malmström P., Nordenskjöld B., Rydén S. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden breast cancer group, and South-East Sweden breast cancer group. Breast Cancer Res. Treat. 2000, 59:69-76.
15. Gonzalez M.E., Duprie M.L., Krueger H., Merajver S.D., Ventura A.C., Toy K.A., Kleer C.G. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 Inhibition in breast cancer. Cancer Res. 2011, 71:2360-2370.
16. Gonzalez M.E., Li X., Toy K., DuPrie M., Ventura A.C., Banerjee M., Ljungman M., Merajver S.D., Kleer C.G. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009, 28:843-853.
17. Gruvberger-Saal S.K., Bendahl P.O., Saal L.H., Laakso M., Hegardt C., Eden P., Peterson C., Malmstrom P., Isola J., Borg A., Ferno M. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin. Cancer Res. 2007, 13:1987-1994.
18. Hansen K.H., Bracken A.P., Pasini D., Dietrich N., Gehani S.S., Monrad A., Rappsilber J., Lerdrup M., Helin K. A model for transmission of the H3K27me3 epigenetic mark. Nat. Cell Biol. 2008, 10:1291-1300.
19. Hawkins R.D., Hon G.C., Lee L.K., Ngo Q., Lister R., Pelizzola M., Edsall L.E., Kuan S., Luu Y., Klugman S., Antosiewicz-Bourget J., Ye Z., Espinoza C., Agarwahl S., Shen L., Ruotti V., Wang W., Stewart R., Thomson J.A., Ecker J.R., Ren B. Distinct epigenomic landscapes of pluripotent and lineage-committed human cells. Cell Stem Cell 2010, 6:479-491.
20. He L.R., Liu M.Z., Li B.K., Rao H.L., Liao Y.J., Guan X.Y., Zeng Y.X., Xie D. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer 2009, 9:461.
21. Holm K., Hegardt C., Staaf J., Vallon-Christersson J., Jonsson G., Olsson H., Borg A., Ringner M. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. 2010, 12:R36.
22. Honeth G., Bendahl P.O., Ringner M., Saal L.H., Gruvberger-Saal S.K., Lovgren K., Grabau D., Ferno M., Borg A., Hegardt C. The CD44+/CD24 - phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008, 10:R53.
23. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., Nobel A., Parker J., Ewend M.G., Sawyer L.R., Wu J., Liu Y., Nanda R., Tretiakova M., Ruiz Orrico A., Dreher D., Palazzo J.P., Perreard L., Nelson E., Mone M., Hansen H., Mullins M., Quackenbush J.F., Ellis M.J., Olopade O.I., Bernard P.S., Perou C.M. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
24. Jirström K., Rydén L., Anagnostaki L., Nordenskjöld B., Stål O., Thorstenson S., Chebil G., Jonsson P.E., Fernö M., Landberg G. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J. Clin. Pathol. 2005, 58:1135-1142.
25. Jones A., Wang H. Polycomb repressive complex 2 in embryonic stem cells: an overview. Protein Cell 2010, 1:1056-1062.
26. Jönsson G., Staaf J., Vallon-Christersson J., Ringner M., Holm K., Hegardt C., Gunnarsson H., Fagerholm R., Strand C., Agnarsson B.A., Kilpivaara O., Luts L., Heikkila P., Aittomaki K., Blomqvist C., Loman N., Malmstrom P., Olsson H., Johannsson O.T., Arason A., Nevanlinna H., Barkardottir R.B., Borg A. Genomic subtypes of breast cancer identified by array comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res. 2010, 12:R42.
27. Jönsson, G., Staaf, J., Vallon-Christersson, J., Ringnér, M., Gruvberger-Saal, S.K., Saal, L.H., Holm, K., Hegardt, C., Arason, A., Fagerholm, R., Persson, C., Grabau, D., Johnsson, E., Lövgren, K., Magnusson, L., Heikkilä, P., Agnarsson, B.A., Johannsson, O.T., Malmström, P., Fernö, M., Olsson, H., Loman, N., Nevanlinna, H., Barkardottir, R.B., Borg, å. The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer. Cancer Res., [Epub ahead of print]. http://dx.doi.org/10.1158/0008-5472.CAN-12-0097.
28. Kamalakaran S., Varadan V., Giercksky Russnes H.E., Levy D., Kendall J., Janevski A., Riggs M., Banerjee N., Synnestvedt M., Schlichting E., Karesen R., Shama Prasada K., Rotti H., Rao R., Rao L., Eric Tang M.H., Satyamoorthy K., Lucito R., Wigler M., Dimitrova N., Naume B., Borresen-Dale A.L., Hicks J.B. DNA methylation patterns in luminal breast cancers differ from non-luminal subtypes and can identify relapse risk independent of other clinical variables. Mol. Oncol. 2011, 5:77-92.
29. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A., Chinnaiyan A.M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U S A 2003, 100:11606-11611.
30. Klintman M., Bendahl P.O., Grabau D., Lovgren K., Malmstrom P., Ferno M. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod. Pathol. 2010, 23:251-259.
31. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., van de Vijver M.J. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007, 9:R65.
32. Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M., Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P., Reinberg D. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl. Acad. Sci. U S A 2005, 102:1859-1864.
33. Lee S.T., Li Z., Wu Z., Aau M., Guan P., Karuturi R.K., Liou Y.C., Yu Q. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol. Cell 2011, 43:798-810.
34. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., Asselin-Labat M.L., Gyorki D.E., Ward T., Partanen A., Feleppa F., Huschtscha L.I., Thorne H.J., Fox S.B., Yan M., French J.D., Brown M.A., Smyth G.K., Visvader J.E., Lindeman G.J. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009, 15:907-913.
35. Makishima H., Jankowska A.M., Tiu R.V., Szpurka H., Sugimoto Y., Hu Z., Saunthararajah Y., Guinta K., Keddache M.A., Putnam P., Sekeres M.A., Moliterno A.R., List A.F., McDevitt M.A., Maciejewski J.P. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010, 24:1799-1804.
36. Malmström P., Bendahl P.O., Boiesen P., Brunner N., Idvall I., Fernö M. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J. Clin. Oncol. 2001, 19:2010-2019.
37. Margueron R., Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
38. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., Yap D., Humphries R.K., Griffith O.L., Shah S., Zhu H., Kimbara M., Shashkin P., Charlot J.F., Tcherpakov M., Corbett R., Tam A., Varhol R., Smailus D., Moksa M., Zhao Y., Delaney A., Qian H., Birol I., Schein J., Moore R., Holt R., Horsman D.E., Connors J.M., Jones S., Aparicio S., Hirst M., Gascoyne R.D., Marra M.A. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
39. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S., Gazdar A., Gray J.W. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
40. Nielsen T.O., Parker J.S., Leung S., Voduc D., Ebbert M., Vickery T., Davies S.R., Snider J., Stijleman I.J., Reed J., Cheang M.C., Mardis E.R., Perou C.M., Bernard P.S., Ellis M.J. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 2010, 16:5222-5232.
41. Nikoloski G., Langemeijer S.M., Kuiper R.P., Knops R., Massop M., Tonnissen E.R., van der Heijden A., Scheele T.N., Vandenberghe P., de Witte T., van der Reijden B.A., Jansen J.H. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 2010, 42:665-667.
42. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., Mohammad H.P., Chen W., Daniel V.C., Yu W., Berman D.M., Jenuwein T., Pruitt K., Sharkis S.J., Watkins D.N., Herman J.G., Baylin S.B. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 2007, 39:237-242.
43. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., Davies S., Fauron C., He X., Hu Z., Quackenbush J.F., Stijleman I.J., Palazzo J., Marron J.S., Nobel A.B., Mardis E., Nielsen T.O., Ellis M.J., Perou C.M., Bernard P.S. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009, 27:1160-1167.
44. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
45. Pietersen A.M., Horlings H.M., Hauptmann M., Langerod A., Ajouaou A., Cornelissen-Steijger P., Wessels L.F., Jonkers J., van de Vijver M.J., van Lohuizen M. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. 2008, 10:R109.
46. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., He X., Perou C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68.
47. Rada-Iglesias A., Enroth S., Andersson R., Wanders A., Pahlman L., Komorowski J., Wadelius C. Histone H3 lysine 27 trimethylation in adult differentiated colon associated to cancer DNA hypermethylation. Epigenetics 2009, 4:107-113.
48. Raman J.D., Mongan N.P., Tickoo S.K., Boorjian S.A., Scherr D.S., Gudas L.J. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 2005, 11:8570-8576.
49. Ringnér M., Fredlund E., Häkkinen J., Borg å., Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One 2011, 6:e17911.
50. Roepman P., Horlings H.M., Krijgsman O., Kok M., Bueno-de-Mesquita J.M., Bender R., Linn S.C., Glas A.M., van de Vijver M.J. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin. Cancer Res. 2009, 15:7003-7011.
51. Ronneberg J.A., Fleischer T., Solvang H.K., Nordgard S.H., Edvardsen H., Potapenko I., Nebdal D., Daviaud C., Gut I., Bukholm I., Naume B., Borresen-Dale A.L., Tost J., Kristensen V. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol. Oncol. 2011, 5:61-76.
52. Rydén L., Jonsson P.E., Chebil G., Dufmats M., Fernö M., Jirström K., Källström A.C., Landberg G., Stål O., Thorstenson S., Nordenskjöld B. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur. J. Cancer 2005, 41:256-264.
53. Rydén L., Landberg G., Stål O., Nordenskjöld B., Fernö M., Bendahl P.O. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Breast Cancer Res. Treat. 2008, 109:351-357.
54. Saal L.H., Johansson P., Holm K., Gruvberger-Saal S.K., She Q.B., Maurer M., Koujak S., Ferrando A.A., Malmstrom P., Memeo L., Isola J., Bendahl P.O., Rosen N., Hibshoosh H., Ringner M., Borg A., Parsons R. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc. Natl. Acad. Sci. U S A 2007, 104:7564-7569.
55. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E., Bergman Y., Simon I., Cedar H. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2007, 39:232-236.
56. Simon J.A., Kingston R.E. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat. Rev. Mol. Cell Biol. 2009, 10:697-708.
57. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U S A 2001, 98:10869-10874.
58. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
59. Squazzo S.L., O'Geen H., Komashko V.M., Krig S.R., Jin V.X., Jang S.W., Margueron R., Reinberg D., Green R., Farnham P.J. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res. 2006, 16:890-900.
60. Staaf J., Jonsson G., Ringner M., Baldetorp B., Borg A. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2011, 13:R129.
61. Staaf J., Jonsson G., Ringner M., Vallon-Christersson J., Grabau D., Arason A., Gunnarsson H., Agnarsson B.A., Malmstrom P.O., Johannsson O.T., Loman N., Barkardottir R.B., Borg A. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2010, 12:R25.
62. Staaf J., Ringner M., Vallon-Christersson J., Jonsson G., Bendahl P.O., Holm K., Arason A., Gunnarsson H., Hegardt C., Agnarsson B.A., Luts L., Grabau D., Ferno M., Malmstrom P., Johannsson O., Loman N., Barkardottir R., Borg A. Identification of subtypes in HER2-positive breast cancer reveals a gene signature prognostic of outcome. J. Clin. Oncol. 2010, 28:1813-1820.
63. Su I.H., Dobenecker M.W., Dickinson E., Oser M., Basavaraj A., Marqueron R., Viale A., Reinberg D., Wulfing C., Tarakhovsky A. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 2005, 121:425-436.
64. Van der Auwera I., Yu W., Suo L., Van Neste L., van Dam P., Van Marck E.A., Pauwels P., Vermeulen P.B., Dirix L.Y., Van Laere S.J. Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One 2010, 5:e12616.
65. Varambally S., Cao Q., Mani R.S., Shankar S., Wang X., Ateeq B., Laxman B., Cao X., Jing X., Ramnarayanan K., Brenner J.C., Yu J., Kim J.H., Han B., Tan P., Kumar-Sinha C., Lonigro R.J., Palanisamy N., Maher C.A., Chinnaiyan A.M. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008, 322:1695-1699.
66. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., Rubin M.A., Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
67. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., Bollen M., Esteller M., Di Croce L., de Launoit Y., Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
68. Wei Y., Xia W., Zhang Z., Liu J., Wang H., Adsay N.V., Albarracin C., Yu D., Abbruzzese J.L., Mills G.B., Bast R.C., Hortobagyi G.N., Hung M.C. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 2008, 47:701-706.
69. Weigelt B., Mackay A., A'Hern R., Natrajan R., Tan D.S., Dowsett M., Ashworth A., Reis-Filho J.S. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010, 11:339-349.
70. Yap D.B., Chu J., Berg T., Schapira M., Cheng S.W., Moradian A., Morin R.D., Mungall A.J., Meissner B., Boyle M., Marquez V.E., Marra M.A., Gascoyne R.D., Humphries R.K., Arrowsmith C.H., Morin G.B., Aparicio S.A. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.